Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Nat Genet. 2013 Aug;45(8):942-6. doi: 10.1038/ng.2696. Epub 2013 Jul 7.
Here we report whole-exome sequencing of individuals with various myeloid malignancies and identify recurrent somatic mutations in SETBP1, consistent with a recent report on atypical chronic myeloid leukemia (aCML). Closely positioned somatic SETBP1 mutations encoding changes in Asp868, Ser869, Gly870, Ile871 and Asp880, which match germline mutations in Schinzel-Giedion syndrome (SGS), were detected in 17% of secondary acute myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases. These results from deep sequencing demonstrate a higher mutational detection rate than reported with conventional sequencing methodology. Mutant cases were associated with advanced age and monosomy 7/deletion 7q (-7/del(7q)) constituting poor prognostic factors. Analysis of serially collected samples indicated that SETBP1 mutations were acquired during leukemic evolution. Transduction with mutant Setbp1 led to the immortalization of mouse myeloid progenitors that showed enhanced proliferative capacity compared to cells transduced with wild-type Setbp1. Somatic mutations of SETBP1 seem to cause gain of function, are associated with myeloid leukemic transformation and convey poor prognosis in myelodysplastic syndromes (MDS) and CMML.
我们在此报告了不同髓系恶性肿瘤个体的全外显子组测序结果,并鉴定出 SETBP1 中的频发体细胞突变,与最近关于非典型慢性髓性白血病 (aCML) 的报道一致。在继发性急性髓细胞性白血病 (sAML) 病例中,有 17%和在慢性髓单核细胞性白血病 (CMML) 病例中,有 15%检测到 SETBP1 编码 Asp868、Ser869、Gly870、Ile871 和 Asp880 改变的体细胞突变,这些突变与 Schinzel-Giedion 综合征 (SGS) 的种系突变相匹配。这些来自深度测序的结果表明突变检测率高于传统测序方法的报道。突变病例与高龄和单体 7/7q 缺失 (-7/del(7q))相关,构成预后不良的因素。对连续采集的样本进行分析表明,SETBP1 突变是在白血病演变过程中获得的。与转导野生型 Setbp1 的细胞相比,转导突变型 Setbp1 导致了小鼠髓系祖细胞的永生化,其增殖能力增强。SETBP1 的体细胞突变似乎导致功能获得,与髓系白血病转化相关,并在骨髓增生异常综合征 (MDS) 和 CMML 中预示不良预后。